Agilent completed the acquisition of Resolution Bioscience for $695m.

Agilent, an American analytical instrumentation development and manufacturing company, completed the acquisition of Resolution Bioscience, a cancer diagnostics solutions provider, for $695m. "The Resolution Bioscience team and powerful technology are strategic and important additions to Agilent’s growing business in precision oncology solutions. This also accelerates our work to more broadly deliver precision oncology testing for patients worldwide with NGS-based diagnostic kits. We’re excited to have Resolution Bioscience joining with us to expand our work in the fight against cancer," Mike McMullen, Agilent President and CEO.